Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20401811 | 0.81 | DDB1 (0.41) | DDB1CRBNCYP19A1MEN1MAPT | |
| SCHEMBL2756273 | 0.77 | KDM1A (0.40) | MAPTTDP1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL2756275 | 0.74 | LMNA (0.42) | ALDH1A1 | |
| SCHEMBL3442854 | 0.73 | MEN1 (0.42) | DDB1CRBNCYP19A1MEN1MAPT | |
| SCHEMBL2756292 | 0.72 | ALDH1A1 (0.38) | MEN1MAPTKMT2ATDP1SMN1; SMN2 | |
| SCHEMBL2756279 | 0.70 | MAPT (0.49) | MAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL24363956 | 0.70 | DRD2 (0.36) | DDB1CRBNCYP19A1ALDH1A1 | |
| SCHEMBL24233839 | 0.70 | DRD2 (0.36) | DDB1CRBNCYP19A1ALDH1A1 | |
| SCHEMBL3333837 | 0.70 | CHRNB2 (0.50) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL12478288 | 0.68 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDB1 339/4885CRBN 1861/4885CYP19A1 4426/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDB1 339/4885CRBN 1861/4885CYP19A1 4426/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDB1 339/4885CRBN 1861/4885CYP19A1 4426/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DDB1 339/4885CRBN 1861/4885CYP19A1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.